19 May 2026 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2026 (‘H1 2026’ or ‘the period’).
Financial highlights
- Revenues up 23% to £3.9 million (H1 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in H1 2026 relative to the equivalent prior period. The Company expects to be at least in line with market expectations for the full year 2026.
- Gross margin increased to 53% (H1 2025: 50%).
- Order book* of £18.1 million; an increase of 38% on 31 March 2025 (H1 2025: £13.1m) and 31% on 30 September 2025 (FY 2025: £13.8m).
- Loss before interest, tax, depreciation and amortization of £0.5 million (H1 2025: £0.7m loss); reflecting increased revenues, offset by full period impact of investments made in the Company’s Innovate, Lead, Scale strategy to deliver sustained revenue growth.
- Cash position of £1.7 million (H1 2025: £5.0m).
- The Group completed a capital raise of £10 million (£9.4 million after placing costs) after the period end, on 27 April 2026, to support its Tech Bio strategy – focussed on accessing novel revenue streams via integrating and partnering the IXITM platform within the wider ecosystem of CROs, clinical trial management and clinical healthcare providers.
*Order book refers to those client contracts that have been signed by the Company but not yet delivered.
Commercial & Operational highlights
- Appointment of Tanya Voloshen as US-based Chief Commercial Officer.
- Commercial agreement signed with Medidata (a Dassault Systèmes company), as a partnership where IXITM augments Medidata’s well-established, clinical trials technology platform used in 80% of FDA novel drug approvals.
- Extension of operational imaging site support into both US and Asia time zones; further enhancing IXICO’s global reach.
- Technology and product roadmap progress announced in Alzheimer’s disease (AD) and Parkinson’s disease (PD) that increases commercial opportunities.
- Projects won across therapeutic areas (further strengthening the Group’s position in rare CNS disorders), clinical phases (incl. Phase 2 & 3), and customer types (incl. a growing number of diagnostic companies).
- Focussed execution on the Innovate, Lead, Scale strategy, delivering a differentiated scientific offering and underpinning revenue, orderbook and commercial pipeline growth.
Post period activity
- £10 million capital raise (£9.4 million net of placing fees) completed on 27 April 2026 to support the Company pursue its TechBio strategy.
- Latest version of IXI™ AI-driven platform (version 10) deployed, increasing data upload and analysis speeds.
Bram Goorden, CEO of IXICO, commented: “The first half of the 2026 financial year saw strong continued revenue growth driven by new contract wins and extensions, and increased biomarker analysis activity. This momentum, combined with improved operational leverage, has delivered an increase in gross margin while our order book has also grown significantly, providing good visibility of future revenues. While we continue to invest for growth, we have reduced our EBITDA loss year-on-year, demonstrating progress towards profitability. I am also very excited about the recently completed capital raise which aims at driving increased value from our IXITM platform as a premium technology. We IXICANs are a mission driven team and for us to be in the middle of the current surge in research into neurodegenerative diseases means everything.”
Company Presentation
As announced on 21 April, Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to the Interim Results and the Company's progress and ongoing strategy via:
The Investor Meet Company platform, this afternoon (19 May 2026) at 16:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.
A recording of the results presentation will be made available on the Group's website.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
